• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Health Product Manufacturers and Innovators COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.

作者信息

Mammen Mathai, Narasimhan Vasant, Kuntz Richard, Lewis-Hall Freda, Poul Mojdeh, Schechter Adam

机构信息

Johnson & Johnson.

Novartis.

出版信息

NAM Perspect. 2022 Jan 18;2022. doi: 10.31478/202201b. eCollection 2022.

DOI:10.31478/202201b
PMID:35402857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8970224/
Abstract
摘要

相似文献

1
Health Product Manufacturers and Innovators COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.健康产品制造商和创新者的 COVID-19 影响评估：经验教训与迫切需求
NAM Perspect. 2022 Jan 18;2022. doi: 10.31478/202201b. eCollection 2022.
2
Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.生物医学研究中的 COVID-19 影响评估：经验教训与迫切需求
NAM Perspect. 2021 Jul 26;2021. doi: 10.31478/202107e. eCollection 2021.
3
Health Care Payers COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.医疗保健支付方对COVID-19的影响评估：经验教训与迫切需求
NAM Perspect. 2021 May 17;2021. doi: 10.31478/202105a. eCollection 2021.
4
Public Health COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.公共卫生领域对新冠疫情的影响评估：经验教训与迫切需求
NAM Perspect. 2021 Apr 7;2021. doi: 10.31478/202104c. eCollection 2021.
5
Digital Health COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.数字健康对COVID-19的影响评估：经验教训与迫切需求。
NAM Perspect. 2022 Jan 18;2022. doi: 10.31478/202201c. eCollection 2022.
6
Patients, Families, and Communities COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.患者、家庭和社区的 COVID-19 影响评估：经验教训与迫切需求
NAM Perspect. 2021 Nov 29;2021. doi: 10.31478/202111c. eCollection 2021.
7
Care Systems COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.医疗系统新冠疫情影响评估：经验教训与迫切需求
NAM Perspect. 2021 Apr 7;2021. doi: 10.31478/202104d. eCollection 2021.
8
Quality, Safety, and Standards Organizations COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.质量、安全与标准组织的新冠疫情影响评估：经验教训与迫切需求
NAM Perspect. 2021 Jul 26;2021. doi: 10.31478/202107d. eCollection 2021.
9
Clinicians and Professional Societies COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.临床医生和专业协会对 COVID-19 的影响评估：经验教训与迫切需求
NAM Perspect. 2021 May 17;2021. doi: 10.31478/202105b. eCollection 2021.
10
Building the Digital Mental Health Ecosystem: Opportunities and Challenges for Mobile Health Innovators.构建数字心理健康生态系统：移动健康创新者的机遇与挑战。
J Med Internet Res. 2021 Oct 13;23(10):e27507. doi: 10.2196/27507.

引用本文的文献

1
Leveraging Resource Centers for Strengthening Immunization Supply Chain.利用资源中心加强免疫供应链。
Cureus. 2024 Apr 25;16(4):e58966. doi: 10.7759/cureus.58966. eCollection 2024 Apr.

本文引用的文献

1
Care Systems COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.医疗系统新冠疫情影响评估：经验教训与迫切需求
NAM Perspect. 2021 Apr 7;2021. doi: 10.31478/202104d. eCollection 2021.
2
Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?受 COVID-19 大流行影响的临床试验：适应性设计能否拯救局面？
Stat Biopharm Res. 2020 Aug 19;12(4):461-477. doi: 10.1080/19466315.2020.1799857.
3
Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials.
Stat Biopharm Res. 2020 Aug 17;12(4):419-426. doi: 10.1080/19466315.2020.1788984.
4
Under a Black Cloud Glimpsing a Silver Lining: Comment on Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic.乌云之下窥见一线曙光：关于2019冠状病毒病大流行期间开展的临床试验的统计问题及建议的评论
Stat Biopharm Res. 2020 Jul 14;12(4):414-418. doi: 10.1080/19466315.2020.1785931.
5
Comment on "Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic".关于《2019冠状病毒病大流行期间开展的临床试验的统计学问题与建议》的评论
Stat Biopharm Res. 2020 Jul 6;12(4):412-413. doi: 10.1080/19466315.2020.1779123.
6
Emerging Lessons From COVID-19 for the US Clinical Research Enterprise.COVID-19给美国临床研究事业带来的新教训。
JAMA. 2021 Mar 23;325(12):1159-1161. doi: 10.1001/jama.2021.3284.
7
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.在初始候选疫苗获得紧急使用授权或批准上市后评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗
JAMA. 2021 Jan 19;325(3):221-222. doi: 10.1001/jama.2020.25127.
8
Deferral of Care for Serious Non-COVID-19 Conditions: A Hidden Harm of COVID-19.严重非新冠病情的医疗延迟：新冠疫情的一种潜在危害
JAMA Intern Med. 2021 Feb 1;181(2):274. doi: 10.1001/jamainternmed.2020.4016.
9
Racial Disparities in Incidence and Outcomes Among Patients With COVID-19.COVID-19 患者的发病和结局中的种族差异。
JAMA Netw Open. 2020 Sep 1;3(9):e2021892. doi: 10.1001/jamanetworkopen.2020.21892.
10
COVID-19 and readjusting clinical trials.2019冠状病毒病与临床试验的重新调整
Lancet. 2020 Aug 22;396(10250):523-524. doi: 10.1016/S0140-6736(20)31787-6.